<DOC>
	<DOCNO>NCT00105196</DOCNO>
	<brief_summary>The purpose 14 week , randomize , double-blind , placebo control study ass safety efficacy aripiprazole placebo adjunctive treatment assign open-label market antidepressant therapy ( ADT ) patient Major Depressive Disorder demonstrate incomplete response prospective eight week trial assign open-label market antidepressant therapy .</brief_summary>
	<brief_title>A Study Aripiprazole Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Men woman , 1865 year old experience single recurrent , nonpsychotic episode Major Depressive Disorder , current episode minimally 8 week duration . Treatment history inadequate response least one three adequate antidepressant trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Single recurrent</keyword>
	<keyword>non-psychotic episode Major Depressive Disorder</keyword>
</DOC>